In Vitro Activity of Iclaprim against Isolates in Two Phase 3 Clinical Trials (REVIVE-1 and -2) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) [Susceptibility]

Iclaprim, a selective bacterial dihydrofolate reductase inhibitor, and other antibiotics were tested against Gram-positive isolates from two Phase 3 studies of ABSSSI (REVIVE-1 and -2). Seven hundred-ninety baseline isolates, including S. aureus, beta-hemolytic streptococci, and S. anginosus Group, underwent antibacterial susceptibility testing. Iclaprim had MIC₉₀ of 0.12μg/mL for S. aureus (0.12μg/mL for methicillin-susceptible, 0.25μg/mL for methicillin-resistant), 0.25μg/mL for beta-hemolytic streptococci and 0.008μg/mL for S. anginosus Group. Iclaprim demonstrated potent activity against these Gram-positive ABSSSI isolates.

http://bit.ly/2FtG45E